CN Patent

CN116284054A — 一种海鞘素类化合物、其抗体药物偶联物及其应用

Assigned to Suzhou Yilian Biomedical Co ltd · Expires 2023-06-23 · 3y expired

What this patent protects

本发明公开了一种海鞘素类化合物、其抗体药物偶联物及其应用。本发明提供了一种海鞘素类化合物或其药学上可接受的盐。本发明的抗体药物偶联物，可以实现肿瘤富集，消除或降低海鞘素作用于非疾病组织而引起的毒副作用，提高治疗效果。

USPTO Abstract

本发明公开了一种海鞘素类化合物、其抗体药物偶联物及其应用。本发明提供了一种海鞘素类化合物或其药学上可接受的盐。本发明的抗体药物偶联物，可以实现肿瘤富集，消除或降低海鞘素作用于非疾病组织而引起的毒副作用，提高治疗效果。

Drugs covered by this patent

Patent Metadata

Patent number
CN116284054A
Jurisdiction
CN
Classification
—
Expires
2023-06-23
Drug substance claim
No
Drug product claim
No
Assignee
Suzhou Yilian Biomedical Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.